Results 1 to 10 of about 10,985 (213)

Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial. [PDF]

PLoS Neglected Tropical Diseases, 2016
BackgroundSSG&PM over 17 days is recommended as first line treatment for visceral leishmaniasis in eastern Africa, but is painful and requires hospitalization.
Monique Wasunna, Simon Njenga, Manica Balasegaram, Neal Alexander, Raymond Omollo, Tansy Edwards, Thomas P C Dorlo, Brima Musa, Mohammed Hassan Sharaf Ali, Mohammed Yasein Elamin, George Kirigi, Rashid Juma, Anke E Kip, Gerard J Schoone, Asrat Hailu, Joseph Olobo, Sally Ellis, Robert Kimutai, Susan Wells, Eltahir Awad Gasim Khalil, Nathalie Strub Wourgaft, Fabiana Alves, Ahmed Musa   +22 more
doaj   +6 more sources

Comparison of meglumine antimoniate versus miltefosine in the treatment of new world cutaneous leishmaniasis: a systematic review and meta-analysis [PDF]

Anais Brasileiros de Dermatologia
Background Cutaneous leishmaniasis (CL) affects up to 1.2 million people annually, mainly in resource-limited regions. Meglumine antimoniate, the standard treatment, is limited by systemic toxicity, injectable administration, and increasing resistance ...
Ana Carolina Putini Vieira, Fernanda Cronemberger Lins, Arianne Costa Baquião   +2 more
doaj   +3 more sources

Pathogen- and Host-Directed Antileishmanial Effects Mediated by Polyhexanide (PHMB) [PDF]

, 2015
BACKGROUND:Cutaneous leishmaniasis (CL) is a neglected tropical disease caused by protozoan parasites of the genus Leishmania. CL causes enormous suffering in many countries worldwide. There is no licensed vaccine against CL, and the chemotherapy options
A Ponte-Sucre, AA Momeni, AF Jebran, AM Carmona-Ribeiro, B Castillo, B Monge-Maillo, Bianca Röger, BLF Schamber-Reis, CM Choi, D Gerit, D Lockwood, DP Eiras, DS Lima-Junior, E Moreno, E Von Stebut, FB Chekeni, G Bringmann, G Carneiro, G Carneiro, G Morizot, G Müller, G Rusciano, G Walls, H Yin, Heidrun Moll, I Arevalo, IJ Gonzalez-Leal, J Alvar, JR Ramírez-Pineda, K Kaehn, Kantaraja Chindera, KT Andrews, L Novo, L-I McCall, Liam Good, Lorenz Meinel, LP O’Malley, M Ghosh, M Yamamoto, M-A Hartley, Maria Cecilia Amstalden, Martina Schultheis, Mary Ann McDowell, MJ Allen, MN Jabbour, MS Bailey, N Datta, Nina Hecht, Nor Fadhilah Kamaruzzaman, R Firdessa, R Hurdayal, Rebuma Firdessa, S Das, S Gupta, S Sundar, S Wessels, Salah A Ben, SK Samal, T Hirsch, T Ikeda, T Lang, T Sato, Tessa Lühmann, Tobias A. Oelschlaeger   +63 more
core   +21 more sources

Antiparasitic properties of miltefosine-based nanoformulations against protozoan pathogen, Acanthamoeba castellanii

Advances in Biomedical and Health Sciences, 2022
Background: Acanthamoeba castellanii genotype T4 is the causative agent of the progressively increasing sight-threatening Acanthamoeba keratitis and central nervous system infections.
Noor Akbar, Roberta Cagliani, Jibran Sualeh Muhammad, Mutasem Rawas-Qalaji, Balsam Qubais Saeed, Naveed Ahmed Khan, Ruqaiyyah Siddiqui   +6 more
doaj   +1 more source

Impavido attenuates inflammation, reduces atherosclerosis, and alters gut microbiota in hyperlipidemic mice

iScience, 2023
Summary: Impavido (Miltefosine) is an FDA-approved drug for treating leishmaniasis and primary amebic meningoencephalitis. We have shown previously that Miltefosine increased cholesterol release and dampened Nlrp3 inflammasome assembly in macrophages ...
C. Alicia Traughber, Amanda J. Iacano, Kalash Neupane, Mariam R. Khan, Emmanuel Opoku, Tina Nunn, Ashutosh Prince, Naseer Sangwan, Stanley L. Hazen, Jonathan D. Smith, Kailash Gulshan   +10 more
doaj   +1 more source

In Vitro Susceptibility to Miltefosine of Leishmania infantum (syn. L. chagasi) Isolates from Different Geographical Areas in Brazil

Microorganisms, 2021
Treatment of visceral leishmaniasis in Brazil still relies on meglumine antimoniate, with less than ideal efficacy and safety, making new therapeutic tools an urgent need.
Caroline Ricce Espada, Erica V. de Castro Levatti, Mariana Côrtes Boité, Dorcas Lamounier, Jorge Alvar, Elisa Cupolillo, Carlos Henrique Nery Costa, Joelle Rode, Silvia R. B. Uliana   +8 more
doaj   +1 more source

In vitro and in vivo miltefosine susceptibility of a Leishmania amazonensis isolate from a patient with diffuse cutaneous leishmaniasis. [PDF]

PLoS Neglected Tropical Diseases, 2014
Miltefosine was the first oral compound approved for visceral leishmaniasis chemotherapy, and its efficacy against Leishmania donovani has been well documented.
Adriano C Coelho, Cristiana T Trinconi, Carlos H N Costa, Silvia R B Uliana   +3 more
doaj   +1 more source

3′Nucleotidase/nuclease is required for Leishmania infantum clinical isolate susceptibility to miltefosineResearch in context

EBioMedicine, 2022
Summary: Background: Miltefosine treatment failure in visceral leishmaniasis in Brazil has been associated with deletion of the miltefosine susceptibility locus (MSL) in Leishmania infantum.
Juliana B.T. Carnielli, Anuja Dave, Audrey Romano, Sarah Forrester, Pedro R. de Faria, Renata Monti-Rocha, Carlos H.N. Costa, Reynaldo Dietze, Ian A. Graham, Jeremy C. Mottram   +9 more
doaj   +1 more source

Synthesis and Antileishmanial Activity of 1,2,4,5-Tetraoxanes against Leishmania donovani [PDF]

, 2020
A chemically diverse range of novel tetraoxanes was synthesized and evaluated in vitro against intramacrophage amastigote forms of Leishmania donovani. All 15 tested tetraoxanes displayed activity, with IC50 values ranging from 2 to 45 µm.
Amado, Patrícia, Cabral, Lília, Cojean, Sandrine, Cristiano, Maria De Lurdes, Loiseau, Philippe M., Pomel, Sébastien   +5 more
core   +1 more source

Miltefosine Suppresses Hepatic Steatosis by Activating AMPK Signal Pathway. [PDF]

PLoS ONE, 2016
BACKGROUND AND PURPOSE:It has been accepted that AMPK (Adenosine monophosphate-activated protein kinase) activation exhibits many beneficial effects on glucolipid metabolism.
Ru Fang, Xudong Zhu, Yaqin Zhu, Xing Tong, Kexue Li, Hui Bai, Xiaoyu Li, Jingjing Ben, Hanwen Zhang, Qing Yang, Qi Chen   +10 more
doaj   +1 more source